Discriminative performance and clinical utility of chronic obstructive pulmonary disease exacerbation categories for
Surya P Bhatt1,2, Amin Adibi3, Sandeep Bodduluri1,2
1Center for Lung Analytics and Imaging Research, University of Alabama at Birmingham, Birmingham, AL, United States.
Rationale:
Treatment initiation or intensification to prevent exacerbations of chronic obstructive pulmonary disease (COPD) is based on the identification of patients with high exacerbation risk. The commonly used high-risk category of at least 2 moderate or 1 severe exacerbation within the prior 12 months has limited supporting evidence.
Objective:
To test the discriminative performance and assess the clinical utility of various COPD exacerbation categories for predicting future exacerbations.
Methods:
In the Genetic Epidemiology of COPD (COPDGene) and NOVEL observational longitudinal study (NOVELTY) cohorts, for each 1-year and 2-year recall periods, we estimated 6 distinct categories of exacerbation frequencies (based on distinct combinations of the number of moderate and severe events), each ascertained in 3 ways: within 1 year, in each of 2 consecutive years, and over a rolling combined 2-year period. We estimated the area under the receiver operating characteristic curve (AUC) and net benefit to evaluate, respectively, the discriminative performance and clinical utility of the resulting 18 categories for predicting the occurrence of 2 moderate or 1 severe exacerbation in the next 12 months.
Measurements And Main Results:
In both COPDGene (n = 3035) and NOVELTY (n = 3080), the category of any moderate or severe exacerbation in the past 2 years had the highest AUC (COPDGene: AUC = 0.69; 95% confidence interval [CI], 0.67-0.71; NOVELTY: AUC = 0.87; 95% CI, 0.85-0.88) for predicting the outcome. The AUC was significantly higher than that of the current standard of at least 2 moderate or at least 1 severe exacerbations in the past year (ΔAUC = 0.03 in COPDGene, and ΔAUC = 0.12 in NOVELTY; both P < .001). In net benefit analysis, exacerbation patterns defined over rolling 2-year windows provided the highest net benefit across a clinically relevant treatment threshold range of 5%-30%.
Conclusions:
At least 1 moderate or 1 severe exacerbation over the previous 2 years has the highest discrimination and confers the highest clinical utility for predicting high COPD exacerbation risk.
Related Concept Videos
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:19Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
01:24Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...